newsfilter
← Latest News
GlobeNewswire·

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT™ related